DBV Technologies S.A. (DBVT): Cash & Equivalents
$194.17M
As of 2025-12-31
$174.90M
As of 2026-06-30
-2.5%
3-year compound annual growth
-0.2%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $194.17M | +498.2% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $32.46M | -77.0% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $141.37M | -32.4% | 2025-04-11, Balance as of period end |
| 2022-12-31 | $209.19M | +170.6% | 2024-03-07, Balance as of period end |
| 2021-12-31 | $77.30M | -60.6% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $196.35M | +1.6% | 2022-03-09, Balance as of period end |
| 2019-12-31 | $193.25M | n/a | 2021-03-17, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $194.17M | +498.2% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $46.63M | +29.3% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $63.03M | -65.5% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $32.49M | -87.4% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $347.56M | +16.5% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $89.25M | +158.2% |
| Curis Inc (CRIS) | 2025-12-31 | $5.06M | -74.7% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $319.77M | +130.0% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $66.05M | +36.0% |
Compare DBVT, FATE, PRME, CGON side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗